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Abstract 
The proportion of elderly in the World’s population is growing, bringing with it an 
increase in age related morbidities. An ability to understand and separate natural 
aging processes from processes specific to morbidities is therefore required to 
understand the heterogeneity observed in the processes of age related organ 
dysfunction. Mechanistic insight into how epigenetic factors regulate aging 
throughout the life course, linked to a decline in renal function with aging, is already 
proving of significant value. Non-coding RNAs have been shown to provide 
epigenetic regulatory circuits within the kidney, reciprocally interacting with DNA 
methylation processes, histone modification, and chromatin. These interactions have 
been demonstrated to reflect the biological age and function of renal allografts. 
Significantly, these epigenetic factors control gene expression and activity in response 
to environmental perturbation and significantly are also key and highly conserved 
signaling pathways known to modulate aging, including the mTOR and the 
insulin/IGF signaling pathways, and the sirtuin family. 
Potential mechanistic links between the epigenetic landscape of aging and renal 
dysfunction have emerged centering on nutrition (phosphate/ phosphatidylcholine), 
gut microbiota and inflammation.  These are directly affected by environmental 
factors, including psychosocial and lifestyle stresses.  
Modification of the epigenome in the kidney via nutritional interventions, or targeting 
the methylome, or chromatin, appear eminently feasible, though caution is merited as 
intergenerational or transgenerational effects in man are not always obvious. 
 
Key Points: 
 
Deaths due to renal dysfunction are growing globally, despite other etiologies 
showing significant decline in the midst of an increasingly aging world 
population.  
 
A mechanistic link is emerging between the epigenetic landscape of aging and 
renal dysfunction based on regulation of aging processes that are common across 
taxa. 
 
Epigenetic regulation of biological ageing in the kidney is influenced directly by 
nutrition, inflammation, the gut microbiome, psychosocial and lifestyle factors. 
 
Models of progeria provide important hypothesis-generating insights for the 
future therapies designed to modify the epigenetic landscape in ageing and 
disease. 
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These interactions indicate new avenues for epigenetic interventions to improve 
renal health, though caution is merited as intergenerational or transgenerational 
effects in man are not always obvious. 
 
 
An introduction to aging in the kidney  
             Geroscience, champions modifiable aspects of biological aging with a view to 
enabling healthier old age. It focuses on common mechanisms of aging, as knowledge 
of the mechanisms and modification of the aging process would be expected to affect 
a broad range of age-related morbidities1,2  
This is in keeping with a major shift in focus by the World Health Organization 
(WHO) in response to the changing demographics of human society and an 
anticipated major burden of age related morbidity and associated societal health care 
costs. By 2020, the number of people aged 60 years and older will outnumber children 
under 5 years old. By 2050, those over 60 years will outnumber those below 14 years 
and constitute 2 billion of the world’s population. Consequently, the WHO places 
increased emphasis on promoting better age related functional health.  
 When evaluated in the context of renal dysfunction, these projections mask the 
impact of age related decline in renal health. Healthy life expectancy (HALE) and 
disability-adjusted life-years (DALYs) data, have indicated deaths due to chronic 
kidney disease (CKD) and some cancers have increased globally despite other 
etiologies showing significant declines in age standardized DALY rates amid rising 
total DALYs3. 
               In this respect, allostatic load can be defined as a composite indicator 
of accumulated biological stress through the life course, which predisposes to 
morbidity in the face of chronic or repeated stress exposure.6 Assessing 
allostatic load is not straightforward and necessitates an integrative analysis of 
a series of biomarkers for stress, aging, and immune function.6 
Additionally, it needs an understanding of epigenetic effects that are differentially 
responsive to environmental changes at different stages in the life course and which 
can be transmitted across generations. These mediate interplay with a range of 
environmental factors, namely psychosocial, socio-economic, nutritional and lifestyle 
factors, that affect health span. 7,8 These are often neglected, or overlooked, in favor 
of mechanistic approaches to understanding renal aging and pathology.  
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Aging and renal dysfunction 
               Distinguishing normal features of the aging process from age-related 
dysfunction is critical to understanding age-related renal health. This is pertinent to a 
range of morbidities, 1 but in the first instance can be exemplified in the context of 
CKD.  The incidence of CKD is ~10-12% in the developed world and growing.9  
Notably, the incidence of CKD parallels chronological aging and almost 50% of end 
stage renal disease (ESRD) patients are 65 years or older.  There seems to be 
heterogeneity in the processes that lead to CKD and factors beyond chronological age, 
such as epigenetic alterations are likely to contribute to a decline in renal functions 
during aging.1  
 Accelerated cellular and physiological aging, however, are already established 
underlying components of a number of morbidities, including CKD.1,10–12  
Correspondingly, CKD patients show a higher incidence of mortality in comparison to 
healthy chronologically age matched individuals, indicative of systemic differences 
layered on top of the dysregulated aging process (Figure 1). As the prevalence of 
CKD parallels an increased prevalence in type-2 diabetes, obesity and a sedentary life 
style,13, an allostatic outcome reflecting the ”burden of life style” may be present next 
to effects of CKD per se. As life style factors directly affect the epigenome,14 the 
effects of epigenetic changes on premature biological aging on renal dysfunction 
merit interest.  
 Loss of plasticity and/or resilience to adaptions to the changing internal 
uremic environment promote vascular aging processes and result in a marked 
discrepancy between the chronological and biological age in CKD.1 As the kidney 
ages chronologically, it displays a range of functional and structural changes 
commensurate with a decrease in glomerular filtration rate, altered sodium regulation, 
increased renin-angiotensin activity, nephron loss, tubular atrophy and diverticula 
formation and decreased tubular number, interstitial fibrosis and basement membrane 
thickening. Parenchymal calcification and renal arterial atherosclerosis are also 
observed.1,15 The uremic phenotype is characterized by many features that typically 
characterize the aged population, such as frailty, depression, cognitive dysfunction, 
sexual dysfunctions, hypogonadism, inflammation, gut dysbiosis, protein-energy 
wasting (PEW), osteoporosis and premature vascular aging, including both 
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atherosclerois (i.e. media thickening) and arteriosclerosis (i.e. media 
calcification).1,16,17    
 Aging in mammals brings an accumulation of senescent cells within the body, 
associated with a loss of functional capacity and characterized by p16ink4a expression 
accompanying cellular growth arrest and a distinct epigenotype.15,18 Change in NF-B 
expression is also typical, with subsequent production of a pro-inflammatory 
senescence associated secretory phenoytpe (SASP) that enables paracrine mediated 
signaling to  adjacent tissue (i.e. bystander effects), which may spread allostatic load 
via secretion of SASP factors and extracellular secretory vesicles via the 
circulation.19,20 Knock-on effects include loss of regenerative capacity and a decrease 
in the availability of nitric oxide.21 As the cardiovascular system is vulnerable to the 
uremic milieu, CKD represents a segmental progeric syndrome.22 Understanding the 
nature of premature aging mechanisms in the perturbed uremic milieu may therefore 
be a prerogative for the rational development of prophylactic measures, as well as 
novel and targeted treatment strategies for renal dysfunction (Figure 1).  
 
Biomarkers of aging in man 
 Increasing chronological age (i.e. years since birth) results in a loss of physical 
capability and function, but the degree of inter-individual variation in people of the 
same chronological age is substantial and adumbrated by a host of environmental, 
genetic and epigenetic contributors. There is thus no ‘gold standard’ for determining 
what constitutes normal aging. Biomarkers of aging (BoA)-related measures of health 
related function should therefore show a significant association with chronological 
age, specifically in the absence of disease23,24 Over the past 50 years a number of 
candidate BoAs have been developed, but all have proven insufficiently robust. 
Systematic reviews of the evidence relating telomere length to mortality/life span and 
to normal age related decline in health measures found few actual mortality studies, 
all of which suffered from survivor bias.7,25–27 Few studies have examined the 
relationship with age-related functional decline, and those that have were equivocal 
and all lacked statistical power.8,28   
 Longitudinal analyses of renal allografts, acting as a source of healthy tissue 
and yielding eGFR as a functional measure of health, have already supported the use 
of CDKN2A expression as a validated biomarker of aging.10,29,30 This has led to the 
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identification of a small miRNA based epigenetic signature associated with regulation 
of the CDKN2 locus that similarly fulfils this criterion and importantly, which is 
active in aging related biochemical pathways, including mTOR and PI3K-AKT, 
conserved across taxa.22 Additionally, these also help regulate chromatin modifiers, 
notably sirtuin family members, thus linking nutrient sensing, cellular metabolism and 
stress defences to age related renal function.31 As such, the activities of these miRNAs 
fall within the nine hallmarks of aging described by Lopez Otin et al (2013)25 that 
represent common denominators of aging in different organisms. Additionally, a 
number are in turn epigenetically regulated by DNA methylation, in keeping with the 
activities of a methylation clock.26 These will be discussed in more detail below. 
 
What is epigenetics? 
         The term epigenetic denotes heritable changes in gene expression that do not 
involve changes to the underlying DNA sequence (i.e. a change in phenotype without 
a change in genotype). Epigenetic regulation facilitates biological plasticity in 
response to environmental changes and enables transgenerational transmission of such 
responses. Addressing age-related changes in epigenetic plasticity is, however, 
challenging, as changes in chromatin, metabolic networks and tissue structure and 
function, appear to underpin a range of age related diseases.34,35 
Two distinct forms of epigenetic inheritance can be described comprising 
those engendering an intergenerational effect and those engendering a 
transgenerational effect. An intergenerational epigenetic effect can be induced 
during  development by the intrauterine environment, thus transmitting them 
from one generation to the next. Transgenerational epigenetic inheritance 
occurs when developmental programming can be transmitted across 
generations not subject to the initial environment stimulus that triggered the 
epigenetic change.36 These are illustrated in Figure 2. Little is known on their 
impact on kidney disease, but a role for intergenerational effects is intuitive1.  
 
Methylation 
           Classically, a loss of genomic methylation and associated heterochromatin has 
been considered features of the aging cellular genome.37 Genomic methylation levels 
display age related epigenetic drift which may directly affect aging processes.38 Age 
related changes in genomic DNA methylation (gDNAm) patterns have also been 
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formulated as an epigenetic clock. These show excellent correlation with 
chronological age33,39,40, though strong correlations with biological age (i.e. age 
related biological function) remain to be proven. Despite this, there is clear evidence 
that changes in the methylome incorporated into epigenetic clocks are predictive of 
all-cause mortality even after adjusting for chronological age and a variety of known 
risk factors 41–43  
A methylome based epigenetic age has been clearly associated with longevity, 
frailty and cognitive/physical fitness. It has been used to demonstrate 
accelerated ageing in a range of conditions including diverse 
neurodegenerative conditions (Parkinson’s disease, Alzheimer’s disease-
related neuropathologies), lung cancer, lifetime stress, menopausal age, 
obesity, metabolic syndrome and coronary heart disease (CHD).44 
Furthermore, it has been shown to reflect accelerated ageing associated with 
environmental stressors, such as poor diet, lack of exercise and chronic low 
grade inflammation45  
More recently, mitochondrial DNA methylation (mtDNAm) at two CpG sites 
(M1215 and M1313) located within the 12S ribosomal RNA gene has been 
demonstrated to correlate inversely with chronological age and thus may 
provide additional epigenetic markers of aging and function, when combined 
with gDNAm markers.32 As a number of genome wide association studies 
have not found a correlation between gDNAm and altered age related gene 
expression,47,48 the incorporation of mtDNAm might help remove any 
equivocation in associations with age related functional parameters of health.  
A number of clinical observations and rodent model studies have indicated the 
changes in the methylome are implicit in the development and progression of 
CKD and are elegantly summarized by Ko and Susztak.49 How any such 
changes relate to  and , or, interplay with the aging process  per se, remains to 
be determined. However, such changes do appear to be associated with renal 
pathology in CKD.50 Notably, they provide a platform for the development of 
metabolic memory, particularly in the context of diabetic nephropathy.51,52  
 
 
Chromatin structure 
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          Chromatin forms through packing of DNA around nucleosomes in a number of 
distinct three dimensional tiers, enabling assembly of higher order structures that 
interact directly with the nuclear envelope and that link otherwise distal genomic 
regions.18,53 Chromatin is transcriptionally inactive and its structure changes with age, 
typified by loss of bound heterochromatin protein 1 (HP1) and H3K9me3 marks.54 
These losses are also observed in human progeric syndromes, such as Hutchinson 
Guilford Progeria Syndrome (HGPS) 57,58 and Werner Syndrome (WS.). 59 
 
Non-coding RNAs 
          Critical mediators of epigenetic plasticity within the cell, and indeed the 
organism, are non coding RNAs (ncRNAs), which effect and co-ordinate regulation 
of a complex range of molecular processes in response to environmental changes. The 
aging process is dramatically influenced by ncRNA activity..60–62 A number of 
distinct classes of ncRNA have been identified, mainly comprising micro (miRNA) 
and long non-coding (lncRNA) RNAs. These provide epigenetic regulatory circuits in 
which lncRNAs, miRNAs and their target transcripts, reciprocally regulate expression 
and include regulatory interaction with DNAm, histone modification, DNA methyl 
transferases (DNMTs) and chromatin, reciprocally controlling their expression and 
activity. 63  
 
Long non-coding RNAs (lncRNAs)  
           LncRNAs constitute non-coding RNAs over 200 nt long, which regulate gene 
expression patterns at the transcriptional, post-transcriptional and post-translational 
levels. LncRNAs display tissue specific gene expression64,65 and are thought to have 
direct roles in the aging process. Putative roles for other lncRNAs have been 
identified in conditions such as heart failure, cardiac autophagy, hypertension, acute 
kidney injury, glomerular diseases, acute allograft rejection and renal cell carcinoma. 
65 LncTERC and lncTERRA are well described in their capacity to regulate telomeres. 
62 Congruent with miRNA regulation of cellular stress and metabolism in aging, 
regulation of Igf2, which encodes an insulin-like growth factor involves lncRNA H19 
regulation of MBD1 (a methyl-CpG-binding domain protein). 66,67,68 Interestingly, 
H19 expression is altered in the kidneys of embryos carried by hyperglycemic 
mothers, providing a conduit for an in utero transgenerational transmission of 
predisposition to related renal dysfunction (Figure 2).  Pertinent to renal dysfunction 
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lncRNA Tug1 has been demonstrated to connect metabolic changes with kidney 
disease in podocytes. In particular, it links mitochondrial bioenergetics, which show 
age related dysfunction in a wide range of species, with nephropathy.69 
 
            More directly adumbrated by aging is CDKN2B-AS/ ANRIL (antisense non-
coding RNA in the INK4 locus). 70 ANRIL is thought to function as a transcriptional 
repressor through interaction with CBX7 and SUZ12, components of polycomb 
repression complexes 1 and 2 respectively, which modify local chromatin status. 71,72 
In the instance of CBX7, ANRIL facilitates recruitment to the CDKN2A locus and 
resultant increase in H3K27methylation, which epigenetically represses CDKN2A 
(p16ink4a) transcription. 71,73  
 
microRNAs 
              MicroRNAs (miRNAs) comprise an evolutionary conserved group of 
ubiquitously expressed single-stranded 20-24nt entities that act as negative post-
transcriptional regulators, either via RNA silencing or translational inhibition. 74,75  
They can show tissue specific expression and are subject to epigenetic regulation by 
differential methylation and chromatin changes. At present 1881 functional miRNAs 
have been characterized for the human microtranscriptome, which are thought to 
target ~ 60% of protein coding genes in man. 76,77 However, over 4000 putative 
candidates have been identified by sequence searches. 78  
 Isoforms (isomiRNAs) of archetypal miRNAs (reference sequence listed in 
miRNA databases), with different 5 prime and/ or 3 prime termini generated from the 
same pre-miRNA have also been identified. Specific isomiRs have been reported as 
substantially more abundant than the archetype miRNA. 79 The available knowledge 
on isomiRNA targets, however, functions and involvement in disease processes 
remains sparse.   
 Conversely, knowledge of archetype miRNAs and their role in the kidney is 
abundant. These have been implicated in renal physiology, development and 
pathology. 65,80–84 
 The interactions of miRNA identified as important for age related renal 
function indicates they facilitate the maintenance of an intracellular regulatory 
network consistent with the original mitochondrion/telomere nucleoprotein 
complex/ribosome (MTR) postulate of Shiels and Davies (2004)85, where intracellular 
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energy availability determines a cell’s capacity for proteosynthesis in response to 
macromolecular damage/redox stress and nutrient availability and utilization via 
mTOR. 85,86 This is in keeping with positive results from interventions promoting 
health span and longevity, such as calorie restriction and administration of rapamycin, 
which work directly through mTOR. 87,88   
 
Epigenetics and progeria 
                To better understand how the epigenetics of aging impacts on the renal 
biology, it can be instructive to examine the pathology of accelerated aging 
syndromes with elements of renal dysfunction. In this respect, Hutchinson-Gilford 
progeria syndrome (HGPS) provides value. HGPS is one progeroid syndrome that 
recapitulates cellular and molecular characteristics of physiological aging and show 
wide changes in the epigenetic landscape. 
 HGPS is a monogenetic disorder caused by mutations in the LMNA gene. 89,90 
It shares along with physiological aging both cellular (abnormal nuclear morphology, 
global genomic hypomethylation and increased DNA damage) and tissue pathology 
(loss of subcutaneous fat, loss of hair, reduced bone mineral density and CVD). 91 
Accumulation of progerin in HGPS is marked by alterations in chromatin structure, 
including a progressive loss of heterochromatin, perturbation of the methylome and 
impaired genome stability. 92–94 Interestingly, low levels of progerin have been found 
in skin and arteries from non-progeria individuals with increasing levels during aging. 
95,96 Progerin expression is also induced by senescence and telomere damage, 97 both 
features of renal aging and dysfunction98 Up-regulation of senescence associated 
secretory phenotype (SASP) factors and increased senescence-associated β-
galactosidase staining frequency have been shown in HGPS mouse models. 99 
Correspondingly, activation of NF-B signaling in this context also provides a link 
between nuclear lamina defects and systemic inflammation; a key feature of both the 
progeric and uremic phenotypes. 100,101 The vascular phenotype of uremia also 
exhibits the calcification and increased arterial stiffness characteristic of HGPS.  One 
direct sequitur from this hypothesis is that other non-communicable diseases may 
generate similar aging effects. This merits further investigation and testing. An 
additional feature of HGPS is elevated hyperphosphatemia, indicative of diminished 
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renal function. Whereas hyperphosphatemia is a classical complication of CKD, it has 
also been observed in and in general population cohorts, linked directly to nutrition1 
 
 
           Analogous to HGPS in many respects is Klotho, mutations in which generate 
progeria with concomitant hyperphosphatemia.  Klotho is critical to modulating the 
function of FGF23, a phosphaturic and calcium and sodium-conserving hormone, as 
part of the maintenance of phosphate and vitamin D homeostasis, in concert with 
parathyroid hormone (PTH).102 FGF23 is also active in bone mineralization and has 
been implicated in the impairment of cardiac volume homeostasis in CKD. Both 
FGF23 and PTH levels are chronically raised due to phosphate retention and 
decreased renal 1,25(OH)2D3 production, resulting in vascular calcification. 103–106 
            Klotho-deficient mice display extensive features of progeria,84 including 
infertility, vascular calcification, atherosclerosis, organ atrophy, osteoporosis, 
peripheral insulin sensitivity, metabolic dysfunction and cognitive changes. 
Polymorphisms in the Klotho gene have been associated with human aging and health 
span. 108 
 
            Recently, the anti-aging properties of Klotho in endothelial cells were 
explained by inhibition of NF-κB translocation from cytoplasm to the nucleus, via 
stabilization of the NF-κB/IKK complex, which protected these cells from 
senescence. 109 There appears to be a strong epigenetic regulation of Klotho 
expression in uremia. Uremic toxins such as indoxyl sulphate induce 
hypermethylation of the Klotho gene110, possibly mediated through oxidative stress 
and induction of pro-inflammatory transcription factors such as NF-κB.111    
Therefore, a reduction in Klotho expression may not only result in cellular 
senescence, but may also inhibit an important negative feedback loop resulting in 
increased inflammation.  
 
Epigenetics and inflammaging 
 An important determinant in the pathogenesis of premature aging in range of 
morbidities at different system levels (from (epi)genetics to the macroscopic 
phenotype) appears to be the presence of inflammation.112 In this respect, there appear 
to be relevant correlates between inflammation in renal dysfunction and aging and 
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“inflammaging” in the general population.1,113,114 The term "inflammaging." has been 
used to describe chronic, low-grade inflammation, which is a proven risk factor for 
morbidity and mortality in the aged. Many age-related morbidities present with an 
underlying component of low-grade inflammation, though its etiology remains 
undetermined.115  
  Both DNA hypermethylation, and telomere shortening linked to 
persistent inflammation have been observed in independent studies on CKD.98 
The former observation, however, is counter-intuitive, as DNA 
hypomethylation is more typical of accelerated aging. 45 Observations of 
hypermethylation in CKD thus merit further study, as they may reflect a 
distinct epigenetic feature of CKD pathology decoupled from natural aging 
processes.  
We have previously indicated associations between inflammatory biomarkers 
on DNA methylation in CKD.113 Inflammation directly affects the activity of 
enzymes involved in the establishment, maintenance and change of epigenetic 
landscape across the lifecourse.116,117 As DNMTs are directly affected by IL-6, 
changes in methylation dynamics can be predicted to lead or predispose to 
subsequent ill health. 
 One example of renal dysfunction linked to methylation status involves 
homocysteine. In CKD, circulating homocysteine levels are elevated, enabling its 
conversion to S-adenosylhomocysteine (SAH). SAH is a competitive inhibitor of 
methyltransferases and thus has a direct effect on the cellular methylome.118 Recent 
evidence has indicated a link between immunosuppressive therapy, aging and 
homocysteine biochemistry in renal transplant recipients.119 Longitudinal analyses of 
aging in CKD have indicated that these patients displayed significantly advanced 
biological age.98 Notably, homocysteine is critical for DNA methylation nucleotide 
biosynthesis and maintenance of genomic integrity.120,121 Impact on the cellular 
methylome in these circumstances seems intuitive, but requires further investigation 
to determine if any changes in its status either drive the accelerated aging, or are a 
consequence of it, or of any clinical interventions.119  
 
 At a cellular level, recent evidence suggests an important role for the SASP in 
the pathogenesis of inflammaging.  Senescent cells are pro-inflammatory 122.123  and 
generation of a SASP appears to be under strong epigenetic control. For example, the 
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histone deacetylase Sirtuin 1 may prevent gene expression of pro-inflammatory 
transcription factors, such as NF-kB as well as transcription of pro-inflammatory 
cytokines, such as IL-6, which play an important role in the conversion to a SASP 
producing cytotype.124 In addition, the Jumonji D3 histone demethylase can induce 
both inflammation as well as senescence.125 These findings are of potential 
significance, as Sirtuin 1 is amendable to pharmacological interventions (e.g. by 
resveratrol), whereas JMJD3/KDM6B can be selectively inhibited by GSK-J4.126 
However, although resveratrol reduced vascular calcification in uremic mice and 
improved aerobic capacity compared to controls,127 the relevance of these 
interventions for human CKD have not been studied yet.  
 
Environmental drivers of epigenetic changes and age related health 
              The questions remain as to exactly (i) how factors in an organism’s external 
environment lead to the molecular pathophysiological changes associated with aging 
and disease? (ii) How such factors may induce heritable transgenerational 
physiological changes? There is now a wealth of information emerging on 
psychosocial drivers of age related health, principally indicating that the early years of 
the life course as a key period for establishment of their effects. 7,128,129 This paradigm 
is encapsulated within the Developmental Origins of Health and Disease.130 As such, 
stressors, both early life and subsequently through the life-course, acting 
cumulatively, interactively or independently, may lead to individual differences in 
health span. Conceptually, allostatic load can therefore integrate a number of 
overlapping bio-psychosocial frameworks that have been formulated to explain these 
differences. 131,132 A full discussion of these is beyond the scope of this review, but is 
elegantly covered by Rubin6  
 
We have also hypothesized that how and when any pathology manifests in the 
kidney is influenced by inter-individual differences in a range of factors (see 
Figure 1 and Figure 3) impacting on the epigenetic landscape. These include 
genetics, lifestyle factors, psychosocial factors and nutrition.133 In particular, it 
is intuitive that such inter-individual differences will impact on organ 
dysfunction and associated co-morbidities, progression rate and both timing 
and severity of associated co-morbidities. Although recently a GWAS study 
showed a relation between CKD progression and SNPs in LINC00923, an 
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RNA gene expressed in the kidney, research into the relation between 
individual risk factors and epigenetic alterations relevant for kidney disease is 
limited134  However, a review of recent literature presents a consistent picture 
on how these might influence the epigenetic landscape of aging and health 
span.135 Significantly, a meta analysis of early life adversity and biological 
ageing (determined by telomere length) also supports the thesis that early 
adversity has long-lasting physiological consequences contributing to disease 
risk and biological aging and hence diseases of ageing.136 Notably, both the 
type and timing of early adversity significantly impacted the association 
with telomere length. This has been paralleled by studies in rodents, which 
have indicated that intrauterine exposure to maternal stress alters 
telomere length in the brain of adult offspring.137 
 
While studies in model organisms37 have indicated that nutrition has 
transgenerational epigenetic effects, in man the majority of evidence comes 
from two cohort studies. These comprise the ‘Dutch birth famine’ and the 
Överkalix studies, which have been reviewed in detail elsewhere.133 Evidence 
from the Dutch birth famine cohort found trans-generational transmission of 
effects, including increased neonatal adiposity and type 2 diabetes and 
cardiovascular disease.138,139 One critical observation in this context, was that 
hypomethylation of the imprinted IGF2 gene was associated with prenatal 
famine and contributory to their associated insulin resistance.140,141. 
Interestingly, IGF2 transcription is regulated by miRNAs implicated in the 
control of age-related renal function.29 Notably, miRNAs 125a-5p, 125b, 96 
and 217, which have been shown to be associated with age-related renal health 
span, all regulate sirtuin targets. As such, the expression levels of these 
biomarkers may provide a platform for a molecular quantification of allostatic 
load linked to physiological function at a given point in the life course.  
 
Inter-individual differences in genomic methylation have also been observed 
in relation to methyl-donor nutrient intake by mothers of children born during 
periods of good food availability or poor food availability. Children born 
during a time of poor food availability, corresponding to higher maternal 
methyl-donor nutrient intake peri-conception, displayed increased methylation 
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of six metastable alleles.142 Methyl donor availability is also directly pertinent 
to renal allograft function and biological aging, as is discussed above.98 
Additionally, genomic hypomethylation, along with telomere attrition, both 
features of advanced biological aging, have been observed in 
socioeconomically deprived individuals in the general population.143,144 This 
correlated with chronic inflammation in such communities and a greater 
burden of morbidity and earlier mortality. Notably, recent evidence has 
indicated that this is also independently associated with nutritionally-driven 
hyperphosphatemia, due to frequent red meat and processed meat 
consumption.145 These findings are also relevant to the growing incidence of 
CKD globally and indicate that nutritionally driven hyperphosphatemia 
associated with lower socioeconomic status and poor eating habits are 
potential contributory factors to CKD and chronic inflammation.145  
The question then arises how nutritionally acquired phosphate affects the epigenome? 
Direct evidence for this in man remains sparse. Recent evidence, however, suggests 
that inorganic phosphate induces aberrant promoter methylation in Endothelial-
Mesenchymal Transition, via altered DNMT1–HDAC2 interaction in human coronary 
endothelial cells, which might contribute to endothelial dysfunction in vivo.146  
 
 
Aging, epigenetics and the microbiome 
Although a discussion on aging and inflammation is incomplete without 
mentioning the microbiome, the effect of the gut microbiota on renal function 
is beyond the scope of this article and has been covered in depth elsewhere.147 
However, central to the inter-relationship between gut microbiota, 
inflammation and the age related renal epigenome is Trimethylamine N-oxide 
(TMAO), a metabolite derived from microbial metabolism, which is found in 
elevated levels in advanced CKD where it is an independent predictor of 
mortality. 148 TMAO is produced from the metabolism of phosphatidylcholine, 
L-carnitine and lecithin, found in red meat, fish and eggs. It is a pro-
atherogenic and pro-inflammatory compound that provides a mechanistic link 
between excess red meat consumption in man linked to both 
hyperphosphatemia and accelerated aging. 145,149,150 Notably in these studies, 
less than 25% of inter-individual variation in inflammatory status was 
16 
 
explainable by biological age, 143  or methylation levels, 151 which suggest that 
the microbiome might have a larger impact on inflammation than anticipated 
based on a pre-existing hypothesis of a linear relationship between biological 
age and SASP related inflammatory status. 
 Mechanistically the cumulative and interactive effects of different processes 
may be at play here. Firstly, nutritionally derived hyperphosphatemia with 
concomitant tubular injury and interstitial fibrosis due to calciprotein particle (CPP) 
generation, and genomic hypomethylation, occurring independently of telomere 
attrition.145 Unsurprisingly, the odds ratio of developing CKD is higher in healthy 
subjects with a serum Pi >4mg/dL152 and a high red meat intake153 Additionally, 
translocation of gut microbiota (and, or endotoxins) into the circulation via disruption, 
or leakage, at colonic epithelial tight junctions through altered occludin and claudin 
expression might also be at play. 154,155  Dysfunction of tight junction proteins has also 
been reported to result in reduced nuclear factor erythroid 2-related factor 2 (Nrf2) 
expression, thus elevating oxidative stress levels.89,129 Elevated microbial endotoxin 
levels have previously been detected in the circulation of uremic patients and 
implicated in generating a pro-inflammatory environment.156 The upshot of such 
processes is an increase in inflammation that has a direct affect on DNMTs and 
histone modifiers, with consequential effects on the epigenome. A direct implication 
of this is that the type and caliber of nutrition across the life course may impact 
significantly on the accrual of allostatic load. Further investigation of these processes 
in the uremic environment is warranted.  
 Modifying the epigenome in aging 
Although this field remains immature within regard to nephrology, a range of 
evidence from model organisms through to man, indicates that nutrition, 
exercise and psychosocial interventions can mitigate the effects of aging.157–160 
What is encouraging, is that such interventions target pathways that have 
already been demonstrated to be important in the epigenetic regulation of age-
related renal function1,22 and include signaling and the nutrient-sensing kinase 
AMPK and mTOR pathways,. The clinical agents metformin and rapamycin 
respectively target these pathways, slowing cellular aging and reducing pro-
inflammatory SASP generation. 161–163 Bromodomain-containing protein 4 
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(BRD4), which binds to acetylated lysines on histones, is also able to inhibit 
generation of a SASP in murine models, but this comes at the expense of 
impairing immune surveillance164  
Modulation of sirtuin biochemistry and insulin/IGF signaling has also been 
demonstrated to have an impact on organismal health span.18,87,160,162,163 
Sirtuins comprise orthologues of yeast Sir2.161 In man, there are seven sirtuins 
which span the intracellular environment across the components of the 
MTR60,86,161. All seven require NAD+ as an obligatory cofactor for their 
activity, though their respective roles differ based on their subcellular 
localization, substrate specificity and spatio-temporal expression. They 
constitute deacetylase, deacylase, desuccinylase, demalonylase, deglutarylase 
and ADP-ribosyltransferase activities that enable dynamic cellular responses 
to metabolic, redox and circadian changes, 165  that fall within the hallmarks of 
aging described by Lopez Otin et al. 32  
 The loss/decline in sirtuin activities with age may facilitate age-associated 
changes in the epigenome and associated transcriptional profiles. Animal studies have 
indicated that loss of function for individual sirtuin family members can have 
dramatic effects on chromatin regulation and lead to progeria and a diverse range of 
age associated pathologies.86 The renal aging miRNAs 125a-5p, 125b, 96 and 217, all 
regulate sirtuin targets. These miRNAs are also active in the mTOR and PI3K 
pathways, which along with the sirtuins, are involved in regulation of inflammation, 
cellular stress responses, autophagy in response to caloric restriction and exercise.166 
Consistent with such a thesis, CR-induced epigenetic changes have also been 
demonstrated to ameliorate age-dependent aberrant methylation in rodent kidneys 
indicative of improved health span.167 
 
 Targeting the cellular methylome also holds promise and a range of chromatin 
remodeling agents are in development for both pre-clinical and clinical testing. A 
number of studies in model organisms have already indicated a functional relationship 
between differential DNA methylation, transcriptomic effects and the development of 
age-related renal pathology.139,140 This is of particular interest, as methylation-based 
epigenetic changes in CKD models have been linked with high serum phosphate,141,168  
so it is intuitive that interventions including synergistic removal of calciprotein 
particles,  might also have some effect in mitigating any adverse effects. 
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Pertinent in the context of uremia is modulation of Klotho methylation, 
possibly in combination with dietary interventions to reduce phosphate intake. 
Klotho promoter methylation is a feature of CKD, but treatment with Rhein 
(an anthraquinone compound used to treat diabetic nephropathy) reverses 
klotho methylation in murine models.87,88 Rhein exhibits various 
renoprotective functions and effectively corrects DNMT1/DNMT3a induced 
klotho hypermethylation.169 
 
Conclusions 
 The epigenetics of aging is clearly important for health span and is 
likely context dependent Consequently, approaches to remodel the epigenome 
need to be investigated across the life course, to determine if their effects are 
uniform, or even reversible, over time, or if they demonstrate effects which 
fall under the aegis of antagonistic pleiotropy.  Cellular senescence, a key 
component of organ and tissue aging, appears to fall within this context, being 
undesirable as we gain biological capital early in the life course, but desirable 
later in the life course to prevent cancers. It is thus intuitive that its associated 
epigenetics might also be subject to context dependent intervention. This 
might be a contributory factor to attempts to functionally reprogram cells from 
older individuals, which despite having a rejuvenated transcriptional profile 
retain some age-related characteristics.170  
How one reconciles changes observed in epigenetic regulation of aging 
processes across the body with differences due to segmental aging and, or, 
tissue or organ specific disease processes, remains to be resolved. Caution 
must therefore be used in interpretation of any initial successes with these 
agents, especially when directly extrapolating information derived from model 
organisms to clinical use in man. The transgenerational effects resulting from 
the use of the endocrine disruptor vinclozolin, for example, did not emerge 
until F1–F4 generations, when animals were found to be associated with 
altered epigenetic programming of the male germ line and display of kidney 
disease, immune system dysfunction, prostate disease, hypercholesterolemia 
and an increased rate of cancer.171 
 Additional approaches targeting modification of the epigenetic landscape include 
cellular reprogramming via miRNA delivery to enhance renal repair, which is also 
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showing promise for use in the clinic,18,161 though it remains pre-clinical at present. 
Additionally, senotherapeutics, especially promising agents that can remove aged 
cells, are also in development and preclinical testing, but their impact on the 
epigenome remains to be established.172 The potential of this approach, however, has 
been elegantly demonstrated recently, with the selective removal of senescent cells by 
apoptosis using a FOXO4 peptide, which restores tissue homeostasis and renal 
function in naturally aged mice.173 
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Figure 1. The epigenetic landscape mediates the interplay between stressors and 
renal dysfunction  
Both exogenous (environmental) and endogenous (physiological) stimuli lead to 
changes in the epigenetic landscape that impact on renal aging and physiology. These 
reflect accumulating allostatic load, both physiologically across the body and at the 
cellular and molecular levels. The resulting functional changes in cellular biology, 
that reflect accelerated aging processes in the organ, act in concert with stress driven 
physiological changes to induce further dysfunction that predisposes to and aids 
progression of disease processes, which may further perturb all the tiers of the 
epigenome.  
 
Figure 2.  Environmental factors and epigenomic alterations. 
Epigenomic changes enable heritable genomic plasticity to environmental stressors. 
The figure illustrates how these can be generated by exposure to a range of diverse 
stimuli, resulting in germline (trans-generational) or somatic cells (inter-generational) 
during pre-natal development, which subsequently influences adult health outcomes. 
Stimuli can also have gender specific effects. DDT for example affects fertility in 
both genders, but only in males is there a specific effect on the kidney, causing a 
change in kidney size in murine models. Multigenerational exposure to the initial 
stimulus and a subsequent intergenerational effect is not observed beyond the F2 
generation. Trans-generational inheritance has a permanent phenotypic effect in F3 
(females/F2 males) (unexposed) and beyond. This is not well documented in humans 
mostly due to the complex physiology and complexity of maternal effects during/after 
gestation (intergenerational effects).  
 
 
Figure 3. Aging and epigenomic changes in the kidney. 
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There is a renal phenotype common to aged and CKD kidneys1, where epigenomic 
changes parallel aging and accelerated aging in CKD. These reflect epigenetic 
responses to exogenous and endogenous stimuli and nutrient availability through the 
life course concomitant with increasing allostatic load. These responses constitute 
changes in a dynamic series of interrelated regulator networks linking the chromatin 
dynamics with the methylome, microtranscriptome, transcriptome and proteome. This 
network is dysregulated and impaired by a range of stressors, including the SASP, and 
CPPs, resulting in further epigenetic changes, impaired immune and anti-aging 
defenses and metabolic dysfunction. 
 
 
 
 
 
 
     
 
 
 
 
 
 
Increasing allostatic load  
over the life course
Phenotype and Dysfunction

Young kidney
Old kidney/ CKD 
Aging trajectory with associated increase in allostatic load
• Telomere attrition
• Deficient response to DNA damage
• Epigenetic changes
• Metabolic shift
• Mitochondrial dysfunction
• Defective ER stress responses
• Decline in autophagy  
• Defective proteostasis
• Decline in regenerative capacities
• Stem cell exhaustion 
• SASP (Low grade chronic 
inflammation)
• Cellular senescence
• Accumulation of damaged cells
• Damage to nuclear envelope (lamina)
• Decline in renal function
• Impaired immune defence
• Low Klotho expression
• Calciprotein particle (CPP)  toxicity
Chromatin remodelling
Transcriptome
DNA methylation
Proteome
Histone composition changes
Histone post-translational modification shift (H3 methylation pattern)
Nucleosome
Heterochromatin/Euchromatin status
Transcription factors binding
Transcriptional co-factors availability
Non somatic mutation
RNA methylation/transcript stability
Alternative splicing
Ribosomes 
Translation
Post-translational modifications
Exogenous factors/endogenous factors
n
cR
N
A
